ISPOR - PCN86 Healthcare Costs and Resource Utilization Associated with PARP Inhibitors in Ovarian Cancer Patients Initially Treated with Platinum-Based Therapy

PCN86 Healthcare Costs and Resource Utilization Associated with PARP Inhibitors in Ovarian Cancer Patients Initially Treated with Platinum-Based Therapy

Abstract

Authors

S. Azmi J. Allaire M. Balk J. Dennison B. Tang

Full Text Cite This Article

Back to Volume 23, Supplemental S2

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now